Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TransCode Therapeutics, Inc. Common Stock (RNAZ)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2880-0.0470 (-3.52%)
At close: 04:00PM EDT
1.3400 +0.05 (+4.04%)
After hours: 04:56PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3350
Open1.2945
Bid1.2100 x 3100
Ask1.2900 x 1400
Day's Range1.2501 - 1.3600
52 Week Range1.1500 - 7.0000
Volume32,109
Avg. Volume40,851
Market Cap16.621M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7620
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    TransCode Therapeutics to Participate at BIO International Convention

    BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the BIO International Convention to be held June 13-16 in San Diego, CA. The in-person venue for the event is the San Diego Convention Center. During the presentation, TransCode’s Chief Executive Officer, Michael Dudley, will discuss the Company's RNA-based scientific discoveries that it believes have the potential to significantly advance the treatmen

  • GlobeNewswire

    TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award

    Funding is part of a 2021 Fast-Track Small Business Innovation Research (SBIR) grant to Support Clinical Development of First-in-Class Therapy for Advanced Solid Tumors First SBIR program milestone achieved in Q1 2022 BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it was awarded the second tranche of funding from a Fast-Track Small Business Innovation Resear

  • GlobeNewswire

    TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference

    BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the Fontainebleau Hotel in Miami Beach at 4441 Collins Avenue. Virtual participation will be staged simultaneously as a live feed and available on-demand. During the presentation, TransCode’s Chief Executive Officer, Michael Dudley, will discuss the Company's RNA-based scien

Advertisement
Advertisement